1.01
+0.04(+3.96%)
Currency In USD
Address
455 East Medical Center Boulevard
Houston, DE 77598
United States of America
Phone
281 651 5150
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
February 01, 2024
| Name | Title | Pay | Year Born |
| Mr. Peter O'Heeron | Founder, Chairperson & Chief Executive Officer | 626,747 | 1964 |
| Mr. Ruben A. Garcia J.D. | General Counsel | 327,381 | 1978 |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer | 361,751 | 1970 |
| Mr. Robert E. Hoffman B.B.A., CPA | Interim Chief Financial Officer & Director | 606,725 | 1966 |
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.